New cell therapy trial targets Tough-to-Treat cancers
NCT ID NCT07266311
Summary
This early-stage study is testing a new type of personalized cell therapy for adults with advanced solid tumors that have a specific marker called Claudin18.2. The main goals are to see if the treatment is safe and if it can shrink tumors. Participants will have their own immune cells collected, modified in a lab to target their cancer, and then infused back into their body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLAUDIN18.2 POSITIVE ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The General Hospital of Western Theater Command
Chengdu, Sichuan, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.